• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ENDOLOGIX INC. AFX2; BIFURCATED STENT GRAFT

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ENDOLOGIX INC. AFX2; BIFURCATED STENT GRAFT Back to Search Results
Model Number BEA25-70/I20-30
Medical Device Problem Codes Failure To Adhere Or Bond (1031); Leak/Splash (1354)
Health Effect - Clinical Codes Aneurysm (1708); Failure of Implant (1924)
Date of Event 03/20/2018
Type of Reportable Event Serious Injury
Additional Manufacturer Narrative
The device involved in the event will not be returned for evaluation as it remains implanted in the patient.If additional information pertinent to the incident is obtained, a follow-up report will be submitted.
 
Event or Problem Description
The patient was treated with afx.During a routine follow-up, a type ia was identified.In addition, aaa sac growth was observed.The patient underwent treatment on (b)(6) 2018; coils which resolved the reported type ia endoleak.The patient condition post treatment is reported as stable.
 
Additional Manufacturer Narrative
Based on the information received at the completion of the clinical evaluation, clinical was unable to confirm the following reported case event: type ia endoleak; sac growth; secondary endovascular procedure; and coils placed due to the lack of medical information available.Cumulative knowledge informed by past assessments of similar complaints was applied to a review of the available medical information.The most likely cause of the proximal loss of seal was the concomitant use with the products outside the ifu, most likely due to the off-label neck anatomy.Procedure related harms and final patient disposition could not be ascertained due to the lack of medical information surrounding the initial implant procedure and the secondary endovascular procedure.Reportedly, the patient is in stable condition post the repair procedure.To date there has been no reports of further negative patient sequalae.A review of the manufacturing lot confirmed all devices met specifications prior to release.The devices remain implanted in the patient and will not returned and no evaluation will be completed.These types of events will be monitored and trended as part of the quality system.(b)(4).
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
AFX2
Common Device Name
BIFURCATED STENT GRAFT
Manufacturer (Section D)
ENDOLOGIX INC.
2 musick
irvine CA 92618
MDR Report Key7428968
Report Number2031527-2018-00327
Device Sequence Number1977030
Product Code MIH
UDI-Device Identifier00818009014832
UDI-Public(01)00818009014832(17)180531
Combination Product (Y/N)N
Initial Reporter StatePA
Initial Reporter CountryUS
PMA/510(K) Number
P040002
Number of Events Summarized1
Summary Report (Y/N)N
Device Implanted Year2017
Reporter Type Manufacturer
Report Source company representative
Initial Reporter Occupation Physician
Type of Report Initial,Followup
Report Date (Section B) 03/20/2018
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? Yes
Operator of Device Physician
Device Expiration Date05/31/2018
Device Model NumberBEA25-70/I20-30
Device Catalogue NumberF00820-100
Device Lot Number1699040007
Was Device Available for Evaluation? No
Was the Report Sent to FDA? No
Initial Date Received by Manufacturer 03/20/2018
Supplement Date Received by Manufacturer03/20/2018
Initial Report FDA Received Date04/13/2018
Supplement Report FDA Received Date05/08/2018
Is This a Single-Use Device that was
Reprocessed and Reused on a Patient? (Y/N)
No
Patient Sequence Number1
Concomitant Medical Products
and Therapy/Usage Dates
VELA SUPRARENAL, LOT 1627285012; VELA SUPRARENAL, LOT 1726317001
Outcome Attributed to Adverse Event Required Intervention;
Patient Age85 YR
-
-